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Abstract
Objective/Background: The majority of multiple sclerosis patients experience impaired walking abil-
ity, which impacts quality of life. Timed 25-foot walk is commonly used to gauge gait impairment but
results can be broadly variable. Objective biological markers that correlate closely with patients’ dis-
ability are needed. Diffusion tensor imaging, quantifying fiber tract integrity, might provide such
information. In this project we analyzed relationships between timed 25-foot walk, conventional and
diffusion tensor imaging magnetic resonance imaging markers.
Design/Methods: A cohort of gait impaired multiple sclerosis patients underwent brain and cervical
spinal cord magnetic resonance imaging. Diffusion tensor imaging mean diffusivity and fractional
anisotropy were measured on the brain corticospinal tracts and spinal restricted field of vision at C2/3.
We analyzed relationships between baseline timed 25-foot walk, conventional and diffusion tensor
imaging magnetic resonance imaging markers.
Results: Multivariate linear regression analysis showed a statistically significant association between
several magnetic resonance imaging and diffusion tensor imaging metrics and timed 25-foot walk: brain
mean diffusivity corticospinal tracts (p¼ 0.004), brain corticospinal tracts axial and radial diffusivity
(P¼ 0.004 and 0.02), grey matter volume (p¼ 0.05), white matter volume (p¼ 0.03) and normalized
brain volume (P¼ 0.01). The linear regression model containing mean diffusivity corticospinal tracts
and controlled for gait assistance was the best fit model (p¼ 0.004).
Conclusions: Our results suggest an association between diffusion tensor imaging metrics and gait
impairment, evidenced by brain mean diffusivity corticospinal tracts and timed 25-foot walk.
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Introduction
Over 80% of multiple sclerosis (MS) patients
experience impaired walking ability during the
course of their illness, and intact ambulation has
been ranked as one of the most important factors
for maintaining a good quality of life.1 Subsequent
need of assistive devices signifies disease progres-
sion and accrual of disability, as reflected by an
emphasis on ambulatory function in the Expanded
Disability Status Scale (EDSS), the most widely
used MS disability scale. Given the influence of
ambulation on everyday life activities, gait impair-
ment has been a target of rehabilitation strategies and
of dalfampridine, a broad spectrum potassium chan-
nel blocker that is the only US Food and Drug
Administration-approved symptomatic treatment for
gait disturbances.24
Among multiple disease monitoring methods utilized
for gait and disability assessment, timed 25 foot walk
(T25FW) has been commonly used in clinical prac-
tice and research trials. Recent meta-analysis found
T25FW to be a well-characterized assessment tool
with high reliability and validity; however, these
advantages are offset by possible practice effects,
differences in administration and day-to-day per-
formance variability, especially in patients with
greater disability.5,6 We have previously shown a
widely variable therapeutic response to dalfampri-
dine using this measure.7 This observation reflects
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an unmet need for more objective assessment meth-
ods correlating closely with patients’ disability.
Conventional magnetic resonance imaging (MRI)
techniques have significant limitations in MS,
including only modest correlation with clinical
measures of disability, such as T25FW.8
Diffusion tensor imaging (DTI) measures diffusional
(Brownian) motion of water molecules, yielding
information about the integrity of white matter
(WM) tracks.9 The combination of mean diffusivity
(MD) and index of fractional anisotropy (FA),
derived from tensor calculations, provides more sen-
sitive information regarding potential interruption of
neural pathways and demyelination than can be seen
on conventional MRI sequences.10,11 The role and
utility of DTI in MS has previously been studied
in the brain.9,12,13 For example, there is a well-
established significant correlation between brain
DTI and conventional MRI metrics, such as T2
lesion volume, grey matter (GM) and WM volume.
Brain DTI metrics have also been shown to correlate
with level of disability as measured by the EDSS and
MS Functional Composite (MFSC).14,15 However,
fewer studies have evaluated DTI metrics in the
spinal cord, and T25FW has not been widely
reported as a separate outcome measure of clinical
disability.15,16
To develop initial pilot data in the field of imaging
biomarkers of clinical disability this project aimed to
identify the relationship between T25FW and both
conventional MRI and DTI metrics. We hypothe-
sized that characterization of neural pathways with
DTI metrics will be associated more closely with
T25FW impairment than will conventional MRI
metrics.
Methods
This study was approved by the institutional
review board of the Icahn School of Medicine at
Mount Sinai and all participants provided informed
consent.
Participants
Patients with a diagnosis of relapsingremitting mul-
tiple sclerosis (RRMS), secondary progressive mul-
tiple sclerosis (SPMS) and primary progressive
multiple sclerosis (PPMS) based on current diagnos-
tic criteria17,18 were enrolled at the Corrine
Goldsmith Dickinson Center for Multiple Sclerosis.
Eligible subjects were all participants in a previously
established database of gait impaired patients we
intended to treat with dalfampridine. Additional
eligibility criteria for this study included treatment
with dalfampridine for 3 months or longer, start of
dalfampridine treatment within 2 years from the
enrolment and at least two T25FW measurements
within 2 years before dalfampridine treatment. Of a
total of 61 patients included in the database, 41 were
excluded from this study because of: (a) dalfampri-
dine treatment duration of less than 3 months
(10 patients); (b) insufficient T25FW measurements
(seven patients); (c) dalfampridine start more than
2 years before enrolment (21 patients); and
(d) patients with uncertain MS diagnosis (three
patients). Thirteen of 18 eligible patients agreed to
participate, and after providing informed consent
underwent MRI of the brain and cervical spine
including DTI scans between October 2013 and
March 2014.
The timed 25 foot walk
The T25FW data were extracted from the medical
records. This measure is obtained during each rou-
tine visit, using a standardized test track, in accord-
ance with methods described in the Administration
and Scoring Manual published by the National
Multiple Sclerosis Society.19 Mean T25FW time
was calculated using data obtained during at least
two separate clinical visits. For this project we
used only dalfampridine pre-treatment baseline
T25FW data.
MRI acquisition
All brain and cervical spinal cord MRI studies were
performed on a 3-Tesla scanner (Magnetom Skyra,
Siemens Healthcare, Erlangen, Germany), using a
20-channel head and spine coil. The brain MRI
protocol included: (a) axial T2 fluid-attenuated
inversion recovery (FLAIR) (TR/TE/TI: 9000/96/
2504 ms; field of vision (FOV): 201 230; matrix:
280 320; yielding 50 contiguous 3 mm-thick
slices); (b) sagittal 3D T1 MPRAGE (TR/TE/TI:
2400/2.1/1000 ms; yielding 0.9 0.9 0.9 mm3 iso-
tropic voxels); (c) single-shot echo planar imaging
(EPI) sequence for DTI (TR/TE: 11300/91 ms;
b-values: 0, 1000 s/mm2, 20 non-collinear directions,
pixel size: 1.95 1.95 mm2 yielding 50 contiguous,
axial 3 mm-thick slices). The cervical spine MRI
protocol included: (a) sagittal short tau inversion
recovery (STIR) (TR/TE: 5840/37 ms; FOV:
236 140; matrix: 192 227; yielding 15 contigu-
ous 4 mm-thick slices); (b) axial T2 MEDIC (TR/TE:
757/14 ms; FOV: 180 180; matrix: 320 356;
yielding 30 contiguous 3 mm-thick slices); (c) sagit-
tal 3D T1 MPRAGE (TR/TE/TI: 1670/2.1/1000 ms;
yielding 1 1 1 mm3 isotropic voxels); (d) axial
single-shot EPI for DTI (TR/TE: 4100/75 ms;
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b-values: 0, 500 s/mm2 20 non-collinear directions,
pixel size: 1.37 1.37 mm2; yielding 30 contiguous,
axial 3 mm-thick slices).
MRI analysis
Lesion volume assessment. The T2-hyperintense and
T1-hypointense lesion volumes were measured by
experienced assessors using a semi-automated seg-
mentation technique based on user-supervised local
thresholding (Jim version 3; Xinapse Systems,
Northants, England).20 The T2-weighted lesion area
was measured by determining lesions’ borders on
FLAIR images. The T1-hypointense lesions were
defined as lesions with signal intensity between cere-
brospinal fluid (CSF) and GM using T1-weighted
scans. The total brain T2 and T1 lesion volume
was calculated by multiplying lesion area by slice
thickness.
Brain volume assessment. The normalized brain
volume, and normalized GM and WM volumes
were measured on lesion-filled T1-weighted image
using SIENAX,21 part of FMRIB Software Library
(FSL).22 Briefly, SIENAX performs brain extraction,
followed by tissue segmentation to separate GM,
WM and CSF. A normalization factor is calculated
based on the subject’s skull size and is applied to the
calculated volumes.
Cervical spinal cord lesion load, volume and cross-
sectional area. Spinal cord lesions hyperintense to
normal-appearing cord tissue were detected and
counted on T2-weighted scans by a neuroradiologist.
Spine volume (SV) and cervical cord cross-sectional
area were measured on the STIR scan from C2 to C3
using a semi-automatic segmentation method.23
First, the sagittal STIR was reformatted and
resampled axially, with the image plane perpendicu-
lar to the cord at the C2/C3 disk level. On this image,
a marker was placed in correspondence to the infer-
ior border of C3. Then, moving back up from C3,
two markers were placed after every two slices, until
the fifth slice from the first marker was reached. An
active surface method was therefore applied, using
the markers of the cord centerline as input. Using
these landmarks, automatic calculation of spine
volume was derived. The mean cord area was calcu-
lated dividing the cord volume by the cord length. To
compensate for the biological variation of structural
measurements unrelated to disease effects, SV was
subsequently normalized dividing by the number of
slices (SVn).24
Brain DTI. Analysis of diffusion-weighted brain and
spine data was performed with the FSL diffusion
toolbox, FDT. First, images were corrected for
head movement and distortions caused by eddy
currents using affine registration of each volume to
the first volume (b¼ 0). FA and MD maps were
calculated by fitting the diffusion tensor at each
voxel using DTIFIT. The FA map was used for
affine registration of individual diffusion images to
the corresponding T1-weighted images using
FLIRT.25,26 All T1-weighted images were then regis-
tered to a common standard space template (MNI
152 atlas at 1 mm resolution) using affine registra-
tion. We used the JHU WM tractography atlas
(thresholded at 25% probability) provided with
FSL to identify the left and right corticospinal tract
(CST).27 Inverting the transformations from diffu-
sion to MNI space calculated above we registered
the JHU WM tractography atlas to each individual
diffusion space and averaged the FA and MD values
within the left and right CST mask (Figure 1). Axial
and radial diffusivity measures were obtained from
the brain DTI scans.
Cervical spinal cord DTI. As described for the
brain, diffusion-weighted images were first corrected
for eddy current distortion and head movements by
affine registration to the first volume (b¼ 0). Then,
coarse masks of the spine were drawn by hand and
the diffusion tensor was fitted at each voxel within
the mask by DTIFIT, resulting in MD and FA
maps of the spine. Next, we created more conserva-
tive masks of the spine, based on the FA map,
of the top five slices, roughly corresponding to
C2C3. The calculated mean FA and MD within
these masks were used for statistical analysis
(Figure 2).
Statistical analysis
All statistical analyses were performed using
IBM SPSS Statistics 22 (Chicago, Illinois, USA).
P values of less than 0.05 were considered statistic-
ally significant. Participants’ demographic data and
imaging data were characterized using descriptive
statistics. Distribution of data was tested using the
ShapiroWilk normality test. Association between
basic demographic data and T25FW was assessed
using Pearson correlation analysis, t-test and analysis
of variance (ANOVA). Multivariate linear regression
was used to identify relationships between T25FW
and MRI data. We first constructed graphic plots of
all independent variables and T25FW to inspect the
linearity of relationships visually. We then con-
structed linear regression models for each imaging






Sixty-one patients, representing the full cohort of
databased dalfampridine-treated patients, were
screened for this project. Eighteen eligible patients
were approached and 13 agreed to participate.
Baseline clinical characteristics are summarized in
Table 1. Our sample was composed of 54% women
and 69% Caucasians, with a mean age of 53 years.
Mean duration of disease was 11 years, 61% patients
had a progressive disease course, and gait assistive
devices were used by 46% of patients (Table 1).
Gait/and imaging assessments
Table 2 illustrates pre-treatment baseline T25FW
results in our cohort. Mean T25FW was 8.26 seconds
(range 4.7512.50) with normal distribution of data
points. Table 3 summarizes conventional MRI par-
ameters, which included T2 lesion volume (T2LV)
and T1 lesion volume (T1LV); GM, WM and nor-
malized brain volume (NBV), cervical cord lesion
load and cervical cord volume at C2/3 (CCV).
Mean T2LV was 5.51 mL (SD 5.54), mean T1LV
was 2.95 mL (SD 3.35). Mean NBV was
1415.49 mL (SD 88.06) and CCV was 164.79 mL
(SD 19.51) (Table 3).
Figure 1. The fractional anisotropy (FA) map with overlaying corticospinal tract (CST) mask derived from
the JHU white matter tractography atlas. Mean FA values were calculated within each CST.
Figure 2. The spine fractional anisotropy (FA) map with overlaying principal vector map. This was used to
identify the main direction of the tracts. The manual C2/C3 mask was used to obtain mean spine FA and mean
diffusivity values.
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MD and FA were measured in brain CSTs and in the
cervical cord at C2/3 region. Axial and radial diffu-
sivity were measured in brain CST. Table 4 further
depicts the DTI metrics in our sample. Mean brain
CST FA was 0.53 (SD 0.038), mean CST MD was
0.8 103mm2/ms (SD 0.06). Mean brain CST axial
diffusivity was 1.32 mm2/s 103 (SD 0.06) and
mean brain CST radial diffusivity was 0.54 mm2/s
 103 (SD 0.06). Mean spinal FA was 0.68
(SD 0.04) and mean MD was 1.08 103mm2/ms
(SD 0.087) (Table 4).
Association between T25FW and baseline clinical
characteristics (age, gender, race, disease duration,
type of MS and gait assistance) were assessed
using t-test and ANOVA. Only disease type
(RRMS, SPMS or PPMS) and type of gait assistance
(none, unilateral or bilateral) were significantly asso-
ciated with T25FW (p¼ 0.05 and 0.003,
respectively).
The relationship between T25FW, conventional MRI
and DTI metrics was assessed using multivariate
linear regression while controlling for gait assistance
as a potential confounder. Graphic representations of
the univariate association between independent vari-
ables (brain and C spine conventional and DTI met-
rics) and T25FW are depicted in Figures 35.
Multivariate linear regression analysis showed a stat-
istically significant association between the follow-
ing MRI and DTI metrics and T25FW: brain MD
CST (p¼ 0.004), brain CST axial and radial diffu-
sivity (p¼ 0.004 and 0.02), GM volume (p¼ 0.05),
WM volume (p¼ 0.03) and NBV (p¼ 0.01). The
linear regression model containing MD CST and
controlled for gait assistance was the best fit model
(p¼ 0.004) (Table 5).
Discussion
This study evaluated relationships between T25FW
and conventional and DTI MRI metrics, thus contri-
buting to existing data exploring the role of advanced
imaging techniques in MS.
The novelty of our approach lies in the attempt to
identify the relationship between modern neuroima-
ging techniques and an objective measure of gait
impairment, noting that only a few previous studies
utilized T25FW in this way. Our analysis of the asso-
ciation between T25FW and basic demographic
characteristics showed a statistically significant cor-
relation between MS clinical phenotype, gait assist-
ive device and T25FW. These findings are in
agreement with earlier work showing that substantial
gait impairment was present in the majority of
patients who transitioned into SPMS28 and serves
as an internal consistency marker for our database.
We found a statistically significant relationship
between gait impairment as measured by the
T25FW and measures of brain volume loss,
Table 1. Baseline clinical characteristics.
Gender Female 54% (7)
Male 46% (6)
Age, years (SD) 53 (13)






Disease course RRMS 39% (5)
SPMS 46% (6)
PPMS 15% (2)
Gait assistance None 54% (7)
Unilateral 23% (3)
Bilateral 23% (3)
DMT agent Interferon beta 1a IM 8% (1)
Natalizumab 8% (1)
Fingolimod 15% (2)
Dimethyl fumarate 15% (2)
No treatment 23% (3)
Glatiramer acetate 31% (4)
RRMS: relapsingremitting multiple sclerosis; SPMS:
secondary progressive multiple sclerosis; PPMS:
primary progressive multiple sclerosis.
Table 2. Timed 25 foot walk (T25FW).














ShapiroWilkes test p¼ 0.600.
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including grey, white and whole-brain atrophy. We
did not find a relationship between T25FW and
lesion metrics in the brain or spinal cord, nor with
spinal cord volume. These findings are congruent
with previous research showing, at most, a weak
relationship between clinical disability and conven-
tional MRI metrics in the brain or spinal cord.29,30
This aspect of our results further emphasizes
Table 3. Conventional MRI metrics.
Study











1 1.53 0.30 660.33 784.26 1444.59 203.76 4
2 1.43 0.64 804.80 739.22 1544.02 163.68 1
3 13.55 9.74 721.53 667.94 1389.47 166.02 2
4 9.21 4.23 681.29 696.54 1377.83 143.44 1
5 1.68 1.25 715.85 730.08 1445.94 163.86 1
6 6.19 4.15 648.73 669.65 1318.37 154.35 2
7 14.22 8.51 648.77 619.54 1268.31 148.99 3
8 2.40 1.87 676.06 669.35 1345.41 193.71 3
9 1.33 0.50 656.50 675.82 1332.32 166.74 1
10 0.45 0.23 809.30 746.77 1556.07 181.03 1
11 1.18 0. 17 739.82 734.04 1473.86 150.31 4
12 15.01 6.31 661.36 747.52 1408.89 141.62 2
13 3.41 0.52 755.63 740.62 1496.25 * *
*Values not calculated.
MRI: magnetic resonance imaging; T1LV: T1 lesion volume; T2LV: T2 lesion volume; GM: grey matter; WM: white matter: NBV: normal-
ized brain volume.










CST (mm2/s 103) Cervical spine CST
Right Left Mean Right Left Mean Left Right Left Right FA MD (mm2/ms)
1 0.576 0.554 0.565 0.743 0.727 0.735 1.234 1.287 0.474 0.471 0.670 1.146
2 0.600 0.576 0.588 0.713 0.729 0.721 1.258 1.262 0.464 0.438 0.719 1.084
3 0.588 0.577 0.582 0.783 0.786 0.7845 1.370 1.340 0.495 0.504 0.693 1.116
4 0.588 0.494 0.541 0.884 0.934 0.909 1.476 1.369 0.664 0.641 0.694 1.016
5 0.570 0.497 0.533 0.776 0.852 0.814 1.361 1.337 0.598 0.496 0.616 1.177
6 0.523 0.529 0.526 0.862 0.798 0.83 1.324 1.415 0.535 0.585 0.770 0.887
7 0.541 0.542 0.542 0.849 0.829 0.839 1.382 1.423 0.553 0.563 0.705 1.04
8 0.546 0.516 0.531 0.772 0.752 0.762 1.230 1.283 0.513 0.517 0.702 1.154
9 0.429 0.483 0.456 0.927 0.828 0.8775 1.313 1.392 0.585 0.695 0.623 1.172
10 0.542 0.522 0.532 0.739 0.757 0.748 1.238 1.239 0.516 0.489 0.665 1.013
11 0.531 0.560 0.545 0.759 0.739 0.749 1.265 1.265 0.476 0.505 0.650 1.082
12 0.459 0.495 0.477 0.878 0.806 0.842 1.298 1.353 0.560 0.640 0.706 0.983
13 0.492 0.487 0.490 0.795 0.833 0.814 1.310 1.247 0.595 0.569 * *
*Values not calculated.
MRI: magnetic resonance imaging; CST: corticospinal tract; FA: fractional anisotropy; MD: mean diffusivity.
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Figure 4. Univariate association between T25FW and conventional brain MRI metrics.
Figure 3. Univariate association between T25FW and brain DTI metrics.
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the need for novel MRI metrics to understand better
the pathological substrate of clinical disability in
MS.
Using DTI metrics, we demonstrated a significant
association between tract integrity of the brain CST
(measured by CST MD) and gait impairment (mea-
sured by T25FW) while controlling for use of an
assistive device. Our findings are in agreement
with a previously observed relationship between
brain CST MD and corticospinal tract impairment
using T25FW as a clinical measure.31 Comparison
of associations between conventional MRI and DTI
metrics and gait dysfunction in our study suggested
DTI metrics, specifically brain CST MD, have the
stronger association with gait impairment. This could
be explained by the higher sensitivity of DTI metrics
for axonal damage and consequent disability. Recent
work by Tovar-Moll and colleagues32 showed a sig-
nificant association between brain CST FA and
motor and sensory functional systems of the EDSS
and T25FW. In their analyses of the univariate rela-
tionship between DTI metrics and EDSS and
T25FW, respectively, FA showed higher statistical
significance. After controlling for chronic T1 lesion
volume, only the association between CST FA
and EDSS, but not T25FW, remained statistically
significant.32 Using a different methodological
approach, we were able to demonstrate an associ-
ation between brain CST MD and T25FW.
However unlike another previous study of cervical
spine DTI metrics and measures of clinical disability
by Naismith and colleagues, we did not demonstrate
a relationship between T25FW and cervical cord
DTI indices.16
The results of our study should be interpreted with
caution and several limitations must be recognized.
Project participants were part of an established data-
base of gait impaired patients we intended to treat
with dalfampridine, and as such had to meet inclu-
sion criteria for this database as well as for the cur-
rent imaging sub-study. Application of these criteria
resulted in a small sample size with consequences on
the generalizability of our analyses. However, this
was a pilot project and we intend to use these data
Figure 5. Univariate association between T25FW and cervical spine DTI and conventional MRI metrics.
Multiple Sclerosis Journal—Experimental, Translational and Clinical
8 www.sagepub.com/msjetc
to develop a larger sample for further investigation,
including novel imaging predictors of dalfampridine
response. Known technical difficulties related to
spinal DTI are due to small cord size and increased
cord mobility resulting in motion artifacts.9 Present
anatomical distortions on DTI maps, often seen in
column-specific tract region of interest, can also pre-
vent accurate localization of anatomical tracts. To
address these technical limitations, we measured
mean FA and MD indices using a single fixed and
easily measured area of interest at C23, as this
region has maximal yield for DTI analysis.33 Using
multiple regions of interest at different cord levels
could provide more data and the possibility of find-
ing additional correlations. A similar technique with
use of an area of interest at the C34 level was pre-
viously reported; however, the sample size in that
study was substantially higher (124 MS patients).15
The atlas methodology used in our project also con-
fers certain analysis limitations. Recognizing that
regional atrophy can cause partial volume effects
that might affect the results, we tried to minimize
this impact by using a very conservative threshold
to create the individual tracts (80% probability).
While using tractography to construct individual
tracts could have been preferable to the atlas meth-
odology, the available diffusion data with 20
directions are unsuitable for a tractography approach,
as a minimum of 25 directions is required to resolve
fibers successfully.34
In conclusion, our study adds to existing data
focusing on the clinical utility of DTI in MS and
constitutes a platform for our ongoing research in
dalfampridine response predictors. We specifically
analyzed brain DTI markers using gait impairment
as the target outcome. We plan to utilize these results
to investigate brain and spinal cord DTI metrics fur-
ther, focusing on brain CST MD as a main candidate
biomarker to predict dalfampridine response.
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